Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
出版年份 2021 全文链接
标题
Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
作者
关键词
-
出版物
Cells
Volume 10, Issue 2, Pages 328
出版商
MDPI AG
发表日期
2021-02-05
DOI
10.3390/cells10020328
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
- (2020) Estela González‐Gualda et al. AGING CELL
- Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers
- (2020) Leopoldo Sitia et al. ACS Omega
- Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma
- (2020) Judith Pape et al. BRITISH JOURNAL OF CANCER
- Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
- (2020) Michal Marczyk et al. Cancers
- Cancer-Associated Fibroblasts: Epigenetic Regulation and Therapeutic Intervention in Breast Cancer
- (2020) Yeuan Ting Lee et al. Cancers
- Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management
- (2020) Lavinia Salama et al. Biomedicines
- Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy
- (2019) Marta Truffi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
- (2019) Tongyan Liu et al. Journal of Hematology & Oncology
- Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
- (2019) Arianna Bonizzi et al. Pharmaceutics
- Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
- (2019) Tom J. Harryvan et al. Journal of Clinical Medicine
- A peek into cancer-associated fibroblasts: origins, functions and translational impact
- (2018) Valerie S. LeBleu et al. Disease Models & Mechanisms
- Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn’s Disease Strictures Ex Vivo
- (2018) Marta Truffi et al. INFLAMMATORY BOWEL DISEASES
- Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics
- (2018) Qin Chen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
- (2017) David Lagares et al. Science Translational Medicine
- H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
- (2017) S. Mazzucchelli et al. Scientific Reports
- Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise
- (2016) Kristopher A. Sarosiek et al. FEBS Journal
- Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer
- (2016) Marta Truffi et al. PHARMACOLOGICAL RESEARCH
- Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
- (2016) Serena Mazzucchelli et al. Oncotarget
- Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression
- (2015) Haojun Luo et al. CANCER LETTERS
- Tumor microenvironment: Sanctuary of the devil
- (2015) Lanlan Hui et al. CANCER LETTERS
- The role of apoptosis in megakaryocytes and platelets
- (2014) Benjamin T. Kile BRITISH JOURNAL OF HAEMATOLOGY
- Antibody–drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin
- (2013) Elisabetta Falvo et al. Nanoscale
- Human ferritin for tumor detection and therapy
- (2013) Kelong Fan et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
- (2012) J. C. Mertens et al. CANCER RESEARCH
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance
- (2010) K. J. Campbell et al. BLOOD
- Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines
- (2010) S. K. Tahir et al. MOLECULAR CANCER THERAPEUTICS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- HPLC–MS/MS determination of a hardly soluble drug in human urine through drug–albumin binding assisted dissolution
- (2008) Ramona Rodila et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started